Swiss pharmaceutical giant Roche saw its shares fall on Monday after investors greeted the company's "Pharma Day" announcements with caution rather than enthusiasm.
Participation certificates dropped 0.8% to CHF 357.50, erasing an earlier 1.4% gain in morning trading, as the Basel-based company confirmed targets it had set previously rather than introducing genuinely new ambitions.
Roche stated it aims to deliver 20 new highly effective drugs by 2030 while joining the global elite in research productivity. The company also plans to broaden its therapeutic footprint, particularly into cardiovascular, kidney and metabolic disease treatments, as part of a strategy to consolidate its position among the world's leading pharma and biotech firms.
To hit those targets, Roche said it has fundamentally restructured its research and development operations over recent years. Project portfolio size was reduced through stricter selection and prioritization, while the aggregate value of remaining programs rose significantly. The company reported that the success rate for projects reaching pivotal Phase III clinical trials was 65% in 2025 and has climbed to over 80% so far in 2026. Development timelines have also shortened alongside cost savings.
Approximately CHF 2 billion within the R&D budget will be reallocated by the end of 2026 — shifted away from less promising initiatives toward programs Roche considers central to its future growth. A portion of those savings is expected to be reinvested into research and emerging technologies rather than simply disappearing from the books.
Recurring annual savings from ongoing efficiency programs are projected at around CHF 1.2 billion in 2026, rising to nearly CHF 1.9 billion per year by 2030. Roche has identified 184 cost-reduction and efficiency measures across the organization, aiming not merely to cut spending but to achieve more with existing resources through faster decision-making and tighter focus on projects capable of reaching approval.
Artificial intelligence is playing an increasingly central role. Roche described a "Lab-in-the-Loop" approach in which AI models analyze large volumes of biological and chemical data, generate predictions, and feed results back into laboratory experiments for validation, creating a continuous improvement cycle. The company said AI or computational analysis has now contributed to approximately 44% of documented decisions in its research pipeline, and the first drug-development projects assisted by AI agents have entered clinical-stage development.
